Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

Abstract Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (I...

Full description

Bibliographic Details

Published in:	Infectious Diseases and Therapy
Main Authors:	Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-03-01
Subjects:	Children Costs and cost analysis Immunization Pneumonia Streptococcus pneumoniae Vaccination
Online Access:	https://doi.org/10.1007/s40121-024-00944-z